New combo therapy aims to tame tough prostate cancer
NCT ID NCT04592237
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a multi-drug approach for men with aggressive variant prostate cancer that has spread. First, patients receive chemotherapy (cabazitaxel and carboplatin) plus an immunotherapy (cetrelimab). Then, they are randomly assigned to take either a PARP inhibitor (niraparib) alone or with cetrelimab to see which better controls the cancer. The study involves 120 participants and aims to measure how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cabazitaxel, carboplatin, cetrelimab, niraparib
- What this could lead to
- If successful, this could offer a new treatment option that helps control aggressive prostate cancer that has spread, potentially extending the time before the disease worsens.
- What could go wrong
- This is an early phase 2 trial with only 120 participants, so results may not apply to all patients. The combination of drugs can cause significant side effects, and it is not yet known if adding cetrelimab maintenance improves outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE VARIANT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a three-drug cocktail outsmart resistant prostate cancer?
- Precision radiation may tame rising PSA after prostate surgery
- New hope for advanced bladder cancer? bevacizumab combo tested
- Supercharged immune cells take on Hard-to-Treat prostate cancer
- New PET scan agent aims to map hidden prostate cancer spread